Structure Therapeutics (GPCR) Competitors $19.61 +0.24 (+1.24%) Closing price 04:00 PM EasternExtended Trading$19.92 +0.32 (+1.61%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GPCR vs. PTCT, MENS, MLTX, MTSR, PTGX, APLS, SRRK, MIRM, MOR, and NAMSShould you be buying Structure Therapeutics stock or one of its competitors? The main competitors of Structure Therapeutics include PTC Therapeutics (PTCT), Jyong Biotech (MENS), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), MorphoSys (MOR), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Structure Therapeutics vs. Its Competitors PTC Therapeutics Jyong Biotech MoonLake Immunotherapeutics Metsera Protagonist Therapeutics Apellis Pharmaceuticals Scholar Rock Mirum Pharmaceuticals MorphoSys NewAmsterdam Pharma PTC Therapeutics (NASDAQ:PTCT) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment. Does the media prefer PTCT or GPCR? In the previous week, PTC Therapeutics had 33 more articles in the media than Structure Therapeutics. MarketBeat recorded 37 mentions for PTC Therapeutics and 4 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.48 beat PTC Therapeutics' score of 0.04 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 7 Negative mention(s) 1 Very Negative mention(s) Neutral Structure Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Is PTCT or GPCR more profitable? PTC Therapeutics has a net margin of 35.65% compared to Structure Therapeutics' net margin of 0.00%. Structure Therapeutics' return on equity of -21.31% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PTC Therapeutics35.65% -106.31% 30.61% Structure Therapeutics N/A -21.31%-20.34% Do analysts rate PTCT or GPCR? PTC Therapeutics presently has a consensus target price of $69.15, suggesting a potential upside of 36.75%. Structure Therapeutics has a consensus target price of $75.71, suggesting a potential upside of 286.10%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.63Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, PTCT or GPCR? PTC Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.89, suggesting that its share price is 289% less volatile than the S&P 500. Do institutionals and insiders hold more shares of PTCT or GPCR? 91.8% of Structure Therapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation & earnings, PTCT or GPCR? Structure Therapeutics has lower revenue, but higher earnings than PTC Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPTC Therapeutics$806.78M4.98-$363.30M$6.977.26Structure TherapeuticsN/AN/A-$122.53M-$1.05-18.68 SummaryPTC Therapeutics beats Structure Therapeutics on 8 of the 15 factors compared between the two stocks. Get Structure Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GPCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GPCR vs. The Competition Export to ExcelMetricStructure TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E RatioN/A21.1431.1525.97Price / SalesN/A401.49476.16171.70Price / CashN/A43.0937.1558.38Price / Book1.468.079.116.39Net Income-$122.53M-$54.72M$3.26B$265.66M7 Day Performance-2.53%2.62%2.11%1.98%1 Month Performance7.81%7.63%5.12%1.33%1 Year Performance-49.91%13.11%31.25%21.15% Structure Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GPCRStructure Therapeutics2.529 of 5 stars$19.61+1.2%$75.71+286.1%-51.1%$1.12BN/A0.00136PTCTPTC Therapeutics4.4522 of 5 stars$43.30-4.6%$70.15+62.0%+44.2%$3.60B$806.78M6.211,410Trending NewsAnalyst ForecastAnalyst RevisionMENSJyong BiotechN/A$49.56+9.3%N/AN/A$3.45BN/A0.0031News CoverageHigh Trading VolumeMLTXMoonLake Immunotherapeutics1.6383 of 5 stars$53.38+1.9%$74.43+39.4%+9.8%$3.35BN/A-19.202MTSRMetseraN/A$30.14-0.9%$55.00+82.5%N/A$3.19BN/A0.0081PTGXProtagonist Therapeutics1.877 of 5 stars$53.75+5.2%$67.20+25.0%+34.9%$3.18B$434.43M76.79120Positive NewsAPLSApellis Pharmaceuticals4.159 of 5 stars$23.85-2.1%$34.12+43.1%-30.7%$3.08B$781.37M-13.10770News CoverageInsider TradeShort Interest ↑SRRKScholar Rock4.5802 of 5 stars$31.46-1.5%$45.14+43.5%+273.5%$3.07B$33.19M-10.81140News CoverageAnalyst ForecastMIRMMirum Pharmaceuticals3.5229 of 5 stars$65.87+9.8%$74.13+12.5%+67.5%$3.01B$336.89M-54.44140Positive NewsHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsNAMSNewAmsterdam Pharma3.4719 of 5 stars$24.37-3.7%$41.20+69.1%+50.2%$2.84B$45.56M-15.044 Related Companies and Tools Related Companies PTC Therapeutics Alternatives Jyong Biotech Alternatives MoonLake Immunotherapeutics Alternatives Metsera Alternatives Protagonist Therapeutics Alternatives Apellis Pharmaceuticals Alternatives Scholar Rock Alternatives Mirum Pharmaceuticals Alternatives MorphoSys Alternatives NewAmsterdam Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GPCR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.